Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oleynikov, Valentin
CONTRAST-2, NCT04347434: Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI	Recruiting	4	300	RoW	Atorvastatin 80mg, Ezetimibe	Penza State University	Myocardial Infarction, Acute, Myocardial Strain, Arterial Stiffness, Quality of Life	11/27	12/27
FORPE, NCT04688320: Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase	Completed	3	310	RoW	Recombinant nonimmunogenic staphylokinase, Fortelyzin, Alteplase, Actillyze	Supergene, LLC	Massive Pulmonary Embolism	07/23	07/23
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
CONTRAST-3, NCT04900155: Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19	Active, not recruiting	N/A	45	RoW	Atorvastatin 80mg, Atorvastatin, Atorvastatin-Ezetimibe	Penza State University	STEMI, Covid19, NSTEMI	11/24	12/24
Solovyev, Oleg V
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
Tavlueva, Evgenia V
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oleynikov, Valentin
CONTRAST-2, NCT04347434: Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI	Recruiting	4	300	RoW	Atorvastatin 80mg, Ezetimibe	Penza State University	Myocardial Infarction, Acute, Myocardial Strain, Arterial Stiffness, Quality of Life	11/27	12/27
FORPE, NCT04688320: Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase	Completed	3	310	RoW	Recombinant nonimmunogenic staphylokinase, Fortelyzin, Alteplase, Actillyze	Supergene, LLC	Massive Pulmonary Embolism	07/23	07/23
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
CONTRAST-3, NCT04900155: Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19	Active, not recruiting	N/A	45	RoW	Atorvastatin 80mg, Atorvastatin, Atorvastatin-Ezetimibe	Penza State University	STEMI, Covid19, NSTEMI	11/24	12/24
Solovyev, Oleg V
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28
Tavlueva, Evgenia V
FORPE-2, NCT06362746: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism	Recruiting	3	486	RoW	Non-immunogenic recombinant staphylokinase, Fortelyzin®, Placebo	Supergene, LLC	Pulmonary Embolism	06/28	12/28